Eupraxia Pharmaceuticals Files Preliminary Prospectus for Public Offering
Eupraxia Pharmaceuticals announced the company has filed a preliminary prospectus supplement to its short form base shelf prospectus dated February 5, 2024 in connection with a proposed public offering of common shares of the company. Cantor and LifeSci Capital are acting as joint book-running managers for the offering. Bloom Burton is also acting as co-manager for the offering.
